These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 10496361

  • 1. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients.
    van Tellingen O, Huizing MT, Panday VR, Schellens JH, Nooijen WJ, Beijnen JH.
    Br J Cancer; 1999 Sep; 81(2):330-5. PubMed ID: 10496361
    [Abstract] [Full Text] [Related]

  • 2. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.
    Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH.
    Cancer Res; 1996 May 01; 56(9):2112-5. PubMed ID: 8616858
    [Abstract] [Full Text] [Related]

  • 3. Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut.
    Bardelmeijer HA, Ouwehand M, Malingré MM, Schellens J, Beijnen JH, van Tellingen O.
    Cancer Chemother Pharmacol; 2002 Feb 01; 49(2):119-25. PubMed ID: 11862425
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo.
    Sparreboom A, Verweij J, van der Burg ME, Loos WJ, Brouwer E, Viganò L, Locatelli A, de Vos AI, Nooter K, Stoter G, Gianni L.
    Clin Cancer Res; 1998 Aug 01; 4(8):1937-42. PubMed ID: 9717822
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel.
    Gelderblom H, Verweij J, van Zomeren DM, Buijs D, Ouwens L, Nooter K, Stoter G, Sparreboom A.
    Clin Cancer Res; 2002 Apr 01; 8(4):1237-41. PubMed ID: 11948138
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Linearized colorimetric assay for cremophor EL: application to pharmacokinetics after 1-hour paclitaxel infusions.
    Brouwer E, Verweij J, Hauns B, Loos WJ, Nooter K, Mross K, Stoter G, Sparreboom A.
    Anal Biochem; 1998 Aug 01; 261(2):198-202. PubMed ID: 9716422
    [Abstract] [Full Text] [Related]

  • 13. Phase I trial of cremophor EL with bolus doxorubicin.
    Millward MJ, Webster LK, Rischin D, Stokes KH, Toner GC, Bishop JF, Olver IN, Linahan BM, Linsenmeyer ME, Woodcock DM.
    Clin Cancer Res; 1998 Oct 01; 4(10):2321-9. PubMed ID: 9796961
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. P450 induction alters paclitaxel pharmacokinetics and tissue distribution with multiple dosing.
    Gustafson DL, Long ME, Bradshaw EL, Merz AL, Kerzic PJ.
    Cancer Chemother Pharmacol; 2005 Sep 01; 56(3):248-54. PubMed ID: 15856231
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A randomized cross-over trial to determine the effect of Cremophor EL on the pharmacodynamics and pharmacokinetics of carboplatin chemotherapy.
    Loi S, Rischin D, Michael M, Yuen K, Stokes KH, Ellis AG, Millward MJ, Webster LK.
    Cancer Chemother Pharmacol; 2004 Nov 01; 54(5):407-14. PubMed ID: 15235821
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.